Pukkila Matti, Kosunen Ari, Ropponen Kirsi, Virtaniemi Jukka, Kellokoski Jari, Kumpulainen Eero, Pirinen Risto, Nuutinen Juhani, Johansson Risto, Kosma Veli-Matti
Otorhinolaryngology-Head and Neck Surgery, Institute of Clinical Medicine, University of Kuopio and Kuopio University Hospital, Kuopio, Finland.
J Clin Pathol. 2007 Mar;60(3):267-72. doi: 10.1136/jcp.2005.034181. Epub 2006 May 26.
Versican, an extracellular matrix proteoglycan, has been noted to be expressed in several malignant tumours and has been suggested to play an important role in cancer development and tumour growth.
To investigate whether the versican expression level in the peritumoural stromal tissue of primary oral squamous cell carcinoma (OSCC) predicts relapse-free or disease-specific survival. Also, to study the associations between versican expression and several other clinicopathological variables, as well as tumour cell proliferation.
Immunohistochemistry was used to study the expression of versican and tumour cell proliferative activity in 139 OSCCs. All pertinent clinical data were collected retrospectively from the hospital records.
In this cohort, versican expression did not correlate with the clinicopathological factors or tumour cell proliferation. In univariate analyses, higher risk for disease recurrence was associated with higher stromal versican expression score (p = 0.02), positive neck node status (p = 0.02), lower Karnofsky performance status (p = 0.03) and higher tumour cell proliferation index (p = 0.04). Increased disease-specific risk of death was associated with high stromal versican expression score (p = 0.005) higher T class (p = 0.002), positive neck node status (p<0.001), higher stage (p<0.001), poorer histological differentiation (p = 0.005), worse general condition of the patient (p = 0.049) and increased tumour cell proliferative index (p = 0.02). In multivariate disease-specific survival analysis, high stromal versican expression score (p = 0.048), poorer histological differentiation (p = 0.047) and higher stage (p = 0.002) independently predicted poorer disease outcome.
In this cohort, increased stromal versican expression correlated with both increased risk for disease recurrence and shortened survival. High stromal versican expression may thus be considered an independent and adverse prognostic marker in OSCC.
多功能蛋白聚糖是一种细胞外基质蛋白聚糖，已被发现在多种恶性肿瘤中表达，并被认为在癌症发展和肿瘤生长中起重要作用。
研究原发性口腔鳞状细胞癌（OSCC）瘤周基质组织中多功能蛋白聚糖的表达水平是否可预测无复发生存期或疾病特异性生存期。此外，研究多功能蛋白聚糖表达与其他几个临床病理变量以及肿瘤细胞增殖之间的关联。
采用免疫组织化学方法研究139例OSCC中多功能蛋白聚糖的表达及肿瘤细胞增殖活性。所有相关临床资料均从医院记录中回顾性收集。
在该队列中，多功能蛋白聚糖表达与临床病理因素或肿瘤细胞增殖无相关性。在单因素分析中，疾病复发风险较高与基质多功能蛋白聚糖表达评分较高（p = 0.02）、颈部淋巴结阳性状态（p = 0.02）、卡诺夫斯基功能状态较低（p = 0.03）以及肿瘤细胞增殖指数较高（p = 0.04）相关。疾病特异性死亡风险增加与基质多功能蛋白聚糖表达评分高（p = 0.005）、T分级较高（p = 0.002）、颈部淋巴结阳性状态（p<0.001）、分期较高（p<0.001）、组织学分化较差（p = 0.005）、患者一般状况较差（p = 0.049）以及肿瘤细胞增殖指数增加（p = 0.02）相关。在多因素疾病特异性生存分析中，基质多功能蛋白聚糖表达评分高（p = 0.048）、组织学分化较差（p = 0.047）和分期较高（p = 0.002）独立预测疾病预后较差。
在该队列中，基质多功能蛋白聚糖表达增加与疾病复发风险增加和生存期缩短相关。因此，基质多功能蛋白聚糖高表达可能被认为是OSCC的一个独立不良预后标志物。
